These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8098243)

  • 21. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
    Van Bortel LM; Breed JG; Joosten J; Kragten JA; Lustermans FA; Mooij JM
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.
    Simon G; Johnson ML
    Clin Exp Hypertens; 1993 May; 15(3):501-9. PubMed ID: 8098243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nebivolol in the management of essential hypertension: a review.
    McNeely W; Goa KL
    Drugs; 1999 Apr; 57(4):633-51. PubMed ID: 10235696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nebivolol: new therapy update.
    Sule SS; Frishman W
    Cardiol Rev; 2006; 14(5):259-64. PubMed ID: 16924166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arterial stiffness, hypertension, and rational use of nebivolol.
    Agabiti-Rosei E; Porteri E; Rizzoni D
    Vasc Health Risk Manag; 2009; 5(1):353-60. PubMed ID: 19475771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of nebivolol.
    Mangrella M; Rossi F; Fici F; Rossi F
    Pharmacol Res; 1998 Dec; 38(6):419-31. PubMed ID: 9990650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA; Black HR
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Third generation beta-blockers: current state of research on vasodilating beta-blockers].
    Ladage D; Reidenbach C; Lichtenthal A; Schwinger R; Brixius K
    Wien Med Wochenschr; 2009; 159(7-8):211-8. PubMed ID: 19412697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
    AlHabeeb W; Mrabeti S; Abdelsalam AAI
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):959-971. PubMed ID: 34106365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of global risk across the continuum of hypertensive heart disease.
    Basile J
    J Clin Hypertens (Greenwich); 2006 Aug; 8(8 Suppl 2):21-30; quiz 39-40. PubMed ID: 16894245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebivolol: more than a highly selective Beta blocker.
    Karter Y
    Recent Pat Cardiovasc Drug Discov; 2007 Jun; 2(2):152-5. PubMed ID: 18221115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.